Ontology highlight
ABSTRACT:
SUBMITTER: Barrientos JC
PROVIDER: S-EPMC6527106 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
Barrientos Jacqueline C JC O'Brien Susan S Brown Jennifer R JR Kay Neil E NE Reddy Nishitha M NM Coutre Steven S Tam Constantine C Mulligan Stephen S Jaeger Ulrich U Devereux Stephen S Pocock Christopher C Robak Tadeusz T Schuster Stephen J SJ Schuh Anna A Gill Devinder D Bloor Adrian A Dearden Claire C Moreno Carol C Cull Gavin G Hamblin Mike M Jones Jeffrey A JA Eckert Karl K Solman Isabelle G IG Suzuki Samuel S Hsu Emily E James Danelle F DF Byrd John C JC Hillmen Peter P
Clinical lymphoma, myeloma & leukemia 20180818 12
<h4>Background</h4>Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).<h4>Patients and methods</h4>Measures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n = 195) or ofatumumab (n = 196) for up to 24 weeks. Endpoints included hematologic function, Functional Ass ...[more]